IDEAYA's IDE849 shows early survival data in relapsed lung cancer

October 23, 2026 6:00 AM

IDEAYA Biosciences (Nasdaq: IDYA) announced updated Phase 1 clinical results for IDE849 (SHR-4849), an investigational antibody-drug conjugate targeting DLL3, at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found